» Articles » PMID: 35909129

Characteristics of Risk Factors for Acute Kidney Injury Among Inpatients Administered Sulfamethoxazole/trimethoprim: a Retrospective Observational Study

Overview
Publisher Biomed Central
Specialty Pharmacology
Date 2022 Jul 31
PMID 35909129
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sulfamethoxazole/trimethoprim (SMX/TMP) potentially increases the serum creatinine levels, resulting in acute kidney injury (AKI). However, the clinical characteristics of the AKI associated with SMX/TMP and the risk factors for its development have not been fully characterized.

Methods: A retrospective cohort observational analysis was conducted on adult inpatients who started SMX/TMP treatment at the Tokyo Women's Medical University, Yachiyo Medical Center, from April 2018 to March 2020. The primary outcome was AKI, defined as an increase in serum creatinine level of ≥ 50% from baseline. Multivariate logistic regression analysis was used to determine the risk factors for the AKI associated with SMX/TMP.

Results: Of the 281 patients, 32 (11.4%) developed AKI. The multivariate logistic regression analysis identified that body mass index (BMI) (odds ratio [OR] = 0.86, 95% confidence interval [95% CI] 0.76-0.97, p < 0.01), presence of hypertension (OR = 2.69, 95% CI 1.11-6.49, p = 0.02), SMX/TMP daily dose (OR = 1.16, 95% CI 1.03-1.30, p = 0.02), and concomitant loop diuretic use (OR = 2.91, 95% CI 1.08-7.78, p = 0.04) were the associated risk factors for AKI in patients who were administered SMX/TMP.

Conclusions: This study showed that low BMI, hypertension, high-dose SMX/TMP, and concomitant loop diuretic use increased the risk of AKI in patients administered SMX/TMP. Clinicians should consider monitoring the renal function in patients at a high risk of AKI.

Citing Articles

Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis.

Xu W, Chen W, Guo J, Zhao L, Ren G, Huang X Bone Marrow Transplant. 2024; 59(8):1076-1083.

PMID: 38658659 DOI: 10.1038/s41409-024-02292-5.


Sulfamethoxazole-induced crystal nephropathy: characterization and prognosis in a case series.

Azencot R, Saint-Jacques C, Haymann J, Frochot V, Daudon M, Letavernier E Sci Rep. 2024; 14(1):6078.

PMID: 38480876 PMC: 10937937. DOI: 10.1038/s41598-024-56322-9.


Pharmacokinetics of Antibacterial Agents in the Elderly: The Body of Evidence.

Butranova O, Ushkalova E, Zyryanov S, Chenkurov M, Baybulatova E Biomedicines. 2023; 11(6).

PMID: 37371728 PMC: 10296334. DOI: 10.3390/biomedicines11061633.

References
1.
Perazella M . Crystal-induced acute renal failure. Am J Med. 1999; 106(4):459-65. DOI: 10.1016/s0002-9343(99)00041-8. View

2.
Moledina D, Perazella M . Drug-Induced Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2017; 12(12):2046-2049. PMC: 5718279. DOI: 10.2215/CJN.07630717. View

3.
Crellin E, Mansfield K, Leyrat C, Nitsch D, Douglas I, Root A . Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study. BMJ. 2018; 360:k341. PMC: 5806507. DOI: 10.1136/bmj.k341. View

4.
Catherinot E, Lanternier F, Bougnoux M, Lecuit M, Couderc L, Lortholary O . Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am. 2010; 24(1):107-38. DOI: 10.1016/j.idc.2009.10.010. View

5.
Masters P, OBryan T, Zurlo J, Miller D, Joshi N . Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 2003; 163(4):402-10. DOI: 10.1001/archinte.163.4.402. View